Neumora Therapeutics (NMRA) Debt Ratio (2025 - 2026)

Neumora Therapeutics (NMRA) posted quarterly Debt Ratio of 0.34 for Q1 2026, up 20.58% quarter-over-quarter from 0.29 in Q4 2025.

Neumora Therapeutics (NMRA) Debt Ratio (2025 - 2026) Analysis & Trends

Neumora Therapeutics' Debt Ratio history runs 2 years deep, the most recent figure standing at 0.34 for Q1 2026.

In Q1 2026, Debt Ratio changed N/A year-over-year to 0.34; the TTM figure through Mar 2026 stood at 0.34 (changed N/A YoY), while the FY2025 annual figure was 0.29, changed N/A from the prior year.
Debt Ratio for Q1 2026 stood at 0.34, up from 0.29 in the prior quarter.
The five-year high for Debt Ratio was 0.34 in Q1 2026, with the low at 0.09 in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	0.05
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	0.12
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	0.47
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	0.26
10	Neumora Therapeutics	296.45 Mn	296.45 Mn	-	0.34

Download Data